Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRMD NASDAQ:GHRS NASDAQ:IMNM NASDAQ:KOD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRMDCorMedix$11.13-2.1%$12.78$3.61▼$17.43$754.84M1.581.37 million shs1.62 million shsGHRSGH Research$17.29+8.1%$12.58$6.00▼$20.50$899.60M0.96199,339 shs153,933 shsIMNMImmunome$9.65+14.9%$8.67$5.15▼$16.81$839.65M1.92906,402 shs1.78 million shsKODKodiak Sciences$4.74-1.5%$3.85$1.92▼$11.60$250.08M2.28350,182 shs207,919 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRMDCorMedix+0.09%+0.80%-21.91%+51.20%+132.04%GHRSGH Research-3.03%+10.50%+25.31%+83.79%+37.14%IMNMImmunome-1.29%-1.75%-8.70%+17.15%-40.68%KODKodiak Sciences-6.96%+23.33%+23.97%+103.81%+62.50%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRMDCorMedix2.6722 of 5 stars4.41.00.00.03.30.00.6GHRSGH Research1.4987 of 5 stars3.51.00.00.02.40.80.0IMNMImmunome2.1482 of 5 stars3.50.00.00.04.12.50.0KODKodiak Sciences4.0205 of 5 stars3.02.00.04.63.13.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRMDCorMedix 2.88Moderate Buy$17.1454.02% UpsideGHRSGH Research 3.00Buy$32.0085.08% UpsideIMNMImmunome 3.00Buy$23.33141.80% UpsideKODKodiak Sciences 2.00Hold$9.0089.87% UpsideCurrent Analyst Ratings BreakdownLatest KOD, GHRS, CRMD, and IMNM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2025CRMDCorMedixD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/30/2025CRMDCorMedixD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold6/30/2025CRMDCorMedixHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$20.006/24/2025CRMDCorMedixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $20.006/24/2025GHRSGH ResearchJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$39.006/23/2025CRMDCorMedixD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.006/20/2025CRMDCorMedixRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$13.00 ➝ $17.006/4/2025GHRSGH ResearchCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$25.005/13/2025GHRSGH ResearchCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/13/2025IMNMImmunomeWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$33.00 ➝ $21.005/9/2025GHRSGH ResearchGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$32.00 ➝ $29.00(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRMDCorMedix$43.47M17.36N/AN/A$1.40 per share7.95GHRSGH ResearchN/AN/AN/AN/A$3.44 per shareN/AIMNMImmunome$9.04M92.88N/AN/A$2.27 per share4.25KODKodiak SciencesN/AN/AN/AN/A$2.86 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRMDCorMedix-$17.93M$0.2250.5911.84N/A20.81%22.57%17.02%8/13/2025 (Estimated)GHRSGH Research-$38.96M-$0.79N/AN/AN/AN/A-19.20%-18.40%9/2/2025 (Estimated)IMNMImmunome-$292.96M-$3.18N/AN/AN/A-1,875.21%-71.65%-60.36%8/11/2025 (Estimated)KODKodiak Sciences-$176.21M-$3.63N/AN/AN/AN/A-115.71%-54.17%8/13/2025 (Estimated)Latest KOD, GHRS, CRMD, and IMNM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025CRMDCorMedix$0.17N/AN/AN/A$29.88 millionN/A8/13/2025Q2 2025KODKodiak Sciences-$1.01N/AN/AN/AN/AN/A8/11/2025Q2 2025IMNMImmunome-$0.52N/AN/AN/A$1.03 millionN/A5/14/2025Q1 2025KODKodiak Sciences-$0.89-$1.09-$0.20-$1.09N/AN/A5/12/2025Q1 2025IMNMImmunome-$0.66-$0.52+$0.14-$0.52$0.46 million$2.93 million5/8/2025Q1 2025GHRSGH Research-$0.61-$0.19+$0.42-$0.19N/AN/A5/6/2025Q1 2025CRMDCorMedix$0.25$0.30+$0.05$0.30$38.90 million$39.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRMDCorMedixN/AN/AN/AN/AN/AGHRSGH ResearchN/AN/AN/AN/AN/AIMNMImmunomeN/AN/AN/AN/AN/AKODKodiak SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRMDCorMedixN/A4.213.99GHRSGH ResearchN/A29.7129.71IMNMImmunomeN/A10.4910.49KODKodiak SciencesN/A4.624.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRMDCorMedix34.18%GHRSGH Research56.90%IMNMImmunome44.58%KODKodiak Sciences89.06%Insider OwnershipCompanyInsider OwnershipCRMDCorMedix5.30%GHRSGH ResearchN/AIMNMImmunome8.60%KODKodiak Sciences45.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRMDCorMedix3067.82 million64.23 millionOptionableGHRSGH Research1052.03 millionN/AOptionableIMNMImmunome4087.01 million79.53 millionOptionableKODKodiak Sciences9052.76 million28.55 millionOptionableKOD, GHRS, CRMD, and IMNM HeadlinesRecent News About These CompaniesEnduring the heat of CaliforniaJuly 15 at 2:27 PM | kodiakdailymirror.comKPenny Stocks To Watch In July 2025July 11, 2025 | finance.yahoo.comNASDAQ:KOD Financials | Kodiak Sciences Inc - Investing.comJuly 10, 2025 | investing.comKodiak Sciences to Host Investor R&D Day on July 16, 2025July 10, 2025 | prnewswire.comPeapod Lane Capital LLC Trims Position in Kodiak Sciences Inc. (NASDAQ:KOD)July 10, 2025 | marketbeat.comKodiak Sciences (NASDAQ:KOD) Stock Price Up 5.1% - Time to Buy?July 9, 2025 | marketbeat.comKodiak Sciences Inc. Advanced Charts | KOD | Barron'sJuly 9, 2025 | barrons.comKodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation Society - MorningstarJune 27, 2025 | morningstar.comMKodiak Sciences to present KSI-101 highlights at the 2025 Congress of the International Ocular Inflammation Society (IOIS)June 27, 2025 | ophthalmologytimes.comOKodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation SocietyJune 25, 2025 | prnewswire.comKodiak Sciences Inc. (NASDAQ:KOD) Short Interest UpdateJune 17, 2025 | marketbeat.comBank of America Corp DE Has $169,000 Stock Holdings in Kodiak Sciences Inc. (NASDAQ:KOD)June 16, 2025 | marketbeat.comWhy Is Kodiak Sciences (KOD) Up 10.5% Since Last Earnings Report?June 13, 2025 | zacks.comTrump’s cuts to fisheries science have industry and conservation groups sounding alarmJune 11, 2025 | kucb.orgKAlaska Aerospace, UAF to partner on new space venturesJune 11, 2025 | kodiakdailymirror.comKRetinal Vein Occlusion Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightJune 5, 2025 | theglobeandmail.comKodiak Sciences to Present at 2025 Jefferies Global Healthcare ConferenceMay 29, 2025 | prnewswire.comKodiak Sciences’ SWOT analysis: eye disease biotech stock at crossroadsMay 29, 2025 | investing.comKodiak Sciences Inc.: Kodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial ResultsMay 15, 2025 | finanznachrichten.deKodiak Sciences Shares Drop After Wider-Than-Expected 1Q LossMay 15, 2025 | marketwatch.comKodiak Q1 Loss Wider Than Expected, Pipeline Development in FocusMay 15, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKOD, GHRS, CRMD, and IMNM Company DescriptionsCorMedix NASDAQ:CRMD$11.13 -0.24 (-2.11%) Closing price 04:00 PM EasternExtended Trading$11.10 -0.03 (-0.22%) As of 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.GH Research NASDAQ:GHRS$17.29 +1.30 (+8.13%) Closing price 04:00 PM EasternExtended Trading$18.35 +1.06 (+6.13%) As of 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.Immunome NASDAQ:IMNM$9.65 +1.25 (+14.88%) Closing price 04:00 PM EasternExtended Trading$9.69 +0.04 (+0.41%) As of 05:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.Kodiak Sciences NASDAQ:KOD$4.74 -0.07 (-1.46%) Closing price 04:00 PM EasternExtended Trading$4.80 +0.06 (+1.37%) As of 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Rocket Lab Gets New Street-High Price Target from Citi Super Micro Stock May Benefit as Cooling Demand Takes Off Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings Salesforce Stock Set for 30% Upside to Reach New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
